Karyopharm Therapeutics Book Value Per Share Growth & History (KPTI)
Karyopharm Therapeutics's book value per share was -$16.00 for fiscal 2025.
View full Karyopharm Therapeutics company overviewKaryopharm Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$16.00 | $6.11 | — |
| 2024 | 2024-12-31 | -$22.11 | -$4.33 | — |
| 2023 | 2023-12-31 | -$17.78 | -$15.57 | — |
| 2022 | 2022-12-31 | -$2.21 | $13.57 | — |
| 2021 | 2021-12-31 | -$15.78 | -$26.03 | — |
| 2020 | 2020-12-31 | $10.26 | -$1.16 | −10.20% |
| 2019 | 2019-12-31 | $11.42 | -$33.75 | −74.71% |
| 2018 | 2018-12-31 | $45.17 | $5.96 | +15.21% |
| 2017 | 2017-12-31 | $39.21 | -$18.89 | −32.52% |
| 2016 | 2016-12-31 | $58.10 | -$24.86 | −29.97% |
| 2015 | 2015-12-31 | $82.96 | -$11.90 | −12.54% |
| 2014 | 2014-12-31 | $94.86 | $16.31 | +20.77% |
| 2013 | 2013-12-31 | $78.55 | $275.48 | — |
| 2012 | 2012-12-31 | -$196.93 | -$7.95 | — |
| 2011 | 2011-12-31 | -$188.98 | — | — |
Karyopharm Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$14.56 | $13.07 | — |
| Q1 2026 | 2026-03-31 | -$11.78 | $12.25 | — |
| Q4 2025 | 2025-12-31 | -$16.00 | $6.11 | — |
| Q3 2025 | 2025-09-30 | -$30.94 | -$11.83 | — |
| Q2 2025 | 2025-06-30 | -$27.63 | -$11.73 | — |
| Q1 2025 | 2025-03-31 | -$24.03 | -$2.27 | — |
| Q4 2024 | 2024-12-31 | -$22.11 | -$4.33 | — |
| Q3 2024 | 2024-09-30 | -$19.11 | -$5.96 | — |
| Q2 2024 | 2024-06-30 | -$15.90 | -$6.56 | — |
| Q1 2024 | 2024-03-31 | -$21.76 | -$15.82 | — |
| Q4 2023 | 2023-12-31 | -$17.78 | -$15.57 | — |
| Q3 2023 | 2023-09-30 | -$13.15 | $12.82 | — |
| Q2 2023 | 2023-06-30 | -$9.35 | $12.52 | — |
| Q1 2023 | 2023-03-31 | -$5.95 | $9.75 | — |
| Q4 2022 | 2022-12-31 | -$2.21 | $13.57 | — |
| Q3 2022 | 2022-09-30 | -$25.97 | -$0.94 | — |
| Q2 2022 | 2022-06-30 | -$21.87 | -$5.32 | — |
| Q1 2022 | 2022-03-31 | -$15.69 | -$7.77 | — |
| Q4 2021 | 2021-12-31 | -$15.78 | -$26.03 | — |
| Q3 2021 | 2021-09-30 | -$25.03 | -$42.12 | — |
| Q2 2021 | 2021-06-30 | -$16.55 | -$43.09 | — |
| Q1 2021 | 2021-03-31 | -$7.92 | -$42.02 | — |
| Q4 2020 | 2020-12-31 | $10.26 | -$1.16 | −10.20% |
| Q3 2020 | 2020-09-30 | $17.09 | $2.77 | +19.33% |
| Q2 2020 | 2020-06-30 | $26.54 | $6.25 | +30.79% |
| Q1 2020 | 2020-03-31 | $34.10 | $4.21 | +14.07% |
| Q4 2019 | 2019-12-31 | $11.42 | -$33.75 | −74.71% |
| Q3 2019 | 2019-09-30 | $14.32 | -$27.98 | −66.14% |
| Q2 2019 | 2019-06-30 | $20.29 | -$32.63 | −61.66% |
| Q1 2019 | 2019-03-31 | $29.89 | $1.04 | +3.61% |
| Q4 2018 | 2018-12-31 | $45.17 | $5.96 | +15.21% |
| Q3 2018 | 2018-09-30 | $42.30 | -$2.61 | −5.81% |
| Q2 2018 | 2018-06-30 | $52.92 | -$0.14 | −0.27% |
| Q1 2018 | 2018-03-31 | $28.85 | -$20.68 | −41.75% |
| Q4 2017 | 2017-12-31 | $39.21 | -$18.89 | −32.52% |
| Q3 2017 | 2017-09-30 | $44.91 | -$18.13 | −28.75% |
| Q2 2017 | 2017-06-30 | $53.07 | -$10.94 | −17.09% |
| Q1 2017 | 2017-03-31 | $49.53 | -$24.39 | −32.99% |
| Q4 2016 | 2016-12-31 | $58.10 | -$24.86 | −29.97% |
| Q3 2016 | 2016-09-30 | $63.03 | -$29.62 | −31.97% |
| Q2 2016 | 2016-06-30 | $64.00 | -$39.90 | −38.40% |
| Q1 2016 | 2016-03-31 | $73.92 | -$41.89 | −36.17% |
| Q4 2015 | 2015-12-31 | $82.96 | -$11.90 | −12.54% |
| Q3 2015 | 2015-09-30 | $92.65 | -$12.12 | −11.57% |
| Q2 2015 | 2015-06-30 | $103.91 | $37.45 | +56.35% |
| Q1 2015 | 2015-03-31 | $115.81 | $42.83 | +58.69% |
| Q4 2014 | 2014-12-31 | $94.86 | $16.31 | +20.77% |
| Q3 2014 | 2014-09-30 | $104.77 | $381.37 | — |
| Q2 2014 | 2014-06-30 | $66.46 | — | — |
| Q1 2014 | 2014-03-31 | $72.98 | — | — |
| Q4 2013 | 2013-12-31 | $78.55 | $275.48 | — |
| Q3 2013 | 2013-09-30 | -$276.60 | — | — |
| Q4 2012 | 2012-12-31 | -$196.93 | — | — |
Karyopharm Therapeutics book value per share trends
Over the last five fiscal years, Karyopharm Therapeutics's book value per share decreased from $10.26 to -$16.00, a change of -$26.25. The latest reported quarter, Q2 2026, shows -$14.56.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Karyopharm Therapeutics source filings ↗